Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID
1194484
Author(s)
Viale, G; Regan, M M; Dell'Orto, P; Mastropasqua, M G; Maiorano, E; Rasmussen, B B; MacGrogan, G; Forbes, J F; Paridaens, R J; Colleoni, M; Láng, I; Thürlimann, B; Mouridsen, H; Mauriac, L; Gelber, R D; Price, K N; Goldhirsch, A; Gusterson, B A; Coates, A S; BIG 1-98 Collaborative and International Breast Cancer Study Groups
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Journal
Annals of oncology
Volume
22
Number
10
Pages / Article-Number
2201-7
Keywords
aromatase inhibitor, breast cancer, prognostic factor, tamoxifen
Abstract
On average, aromatase inhibitors are better than tamoxifen when used as initial or sequential therapy for postmenopausal women with endocrine-responsive early breast cancer. Because there may be contraindications to their use based on side-effects or cost, we investigated subgroups in which aromatase inhibitors may be more or less important.
